On October 14, 2026, MaxCyte, Inc. issued a press release announcing preliminary, unaudited revenue results for the third quarter ended September 30, 2026, and increasing its full-year 2026 revenue guidance. The company reported core business revenue of approximately $8.1 million for the third quarter, representing a 26% increase compared to the same period in 2025. Additionally, the company recognized more than $1.0 million in Strategic Platform License (SPL) Program-related revenue, which included a milestone payment of $1.0 million during the quarter.
MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million, up from the previous forecast of $30 million to $32 million. The updated guidance consists of approximately $28 million in core business revenue, compared to the prior range of $25 million to $27 million, and approximately $6 million in SPL Program-related revenue, compared to the prior estimate of approximately $5 million. The SPL revenue guidance includes approximately $4 million from milestone payments and approximately $2 million from commercial royalties.
The company stated that preliminary results for the third quarter and the second half of the year are ahead of expectations, driven by accelerated instrument purchasing from a large customer. MaxCyte will report full financial results, including royalty revenue, on November 10, 2026, during its third quarter 2026 earnings conference call.
